What is Zymeworks's D&A?

Zymeworks (ZYME) reported D&A of $176K in Q1 2026.

How has Zymeworks's D&A changed year-over-year?

Zymeworks's D&A decreased by 89.1% year-over-year, from $1.62M to $176K.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Zymeworks ZYME D&A

D&A at other companies

PfizerPFE

$1.61B+33.2%

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

Charles River LaboratoriesCRL

$67.15M-44.2%

Adaptive BiotechnologiesADPT

$419K0.0%

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's D&A?: Zymeworks (ZYME) reported D&A of $176K in Q1 2026.
How has Zymeworks's D&A changed year-over-year?: Zymeworks's D&A decreased by 89.1% year-over-year, from $1.62M to $176K.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.